Infertility Drugs
Infertility is a worldwide health issue as its affects both men and women. Infertility in females occur as a result of increasing age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages whereas in males infertility occur as a result of erectile dysfunction, low sperm count, abnormal sperms, etc. Increasing prevalence of infertility is expected to propel demand for the infertility drugs.
The Infertility Drugs Market studied was anticipated to join up a CAGR of 5.8% throughout the forecast period. The major factors attributing to the growth of industry are significant changes in lifestyle which contributed to a rise in the amount of (PCOS) Polycystic ovary syndrome cases, urinary, and breast cancers. The rise in the prevalence of cancers resulting in increased exposure to radiation which leads to infertility. According to the U.S. Department of Health and Human Services (HHS) report, in 2019, PCOS is a major health problem that affects 1 in 10 women of childbearing age over the globe. Thus, rising gynecological disorders resulting in decreased fertility rate is likely to fuel the global infertility drugs market.
According to World Health Organization (WHO) 2012 report, infertility affects one out of four couples in emerging economies. Many researchers work towards finding an efficient treatment for the infertility. For instance, in 2018 at Ben-Gurion University (BGU), Israel researchers were developing a new, single-dose infertility treatment predicated on a brand new compound. The new treatment, produced by the BGU researchers, stimulates the expression of the telomerase and re-elongates the telomeres, protecting the cells from damage.
Read More@ https://bit.ly/3zFTjbO
